Document is current
Any future updates will be listed below
-
Authors
J. Cockcroft, Emma https://orcid.org/0000-0003-3798-9492
Chithuranjan, Dillon
Narendran, Parth https://orcid.org/0000-0002-4583-8793
C. Andrews, Robert https://orcid.org/0000-0003-4939-1738
P. Dias, Renuka https://orcid.org/0000-0002-5743-1077
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research
- License Information
-
More Information
Article History
Received: 22 January 2024
Accepted: 25 March 2025
First Online: 1 May 2025
Declarations
:
: Not applicable.
: Not applicable.
: RPD has received honoraria from Sanofi for participation in an advisory board on Teplizumab. EJC, DC, RCA and PN declare that they have no competing interest, financial or otherwise. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
: All data generated or analysed during this study are included in this published article.
